Company Number: SC679322

Analysis Date: 2025-07-29 12:57 UTC

Financial Health Assessment for Revolutionary Technologies Group Limited

---

1. Financial Health Score: D

Explanation:
The company shows persistent negative net current assets and shareholders' funds over multiple years, indicating ongoing deficits and financial strain. While it remains active and compliant with filings, its balance sheet reveals symptoms of financial distress. This warrants a cautious rating reflecting vulnerability and the need for corrective action.

---

2. Key Vital Signs

Metric	2023 Value (£)	Interpretation
Current Liabilities	4,063	Short-term debts due within a year; modest absolute value.
Net Current Assets	-4,063	Negative working capital; unable to cover short-term debts.
Total Assets Less Current Liabilities	-4,063	Indicates overall net liabilities instead of assets.
Shareholders’ Funds	-4,063	Negative equity; accumulated losses exceed capital.
Share Capital	1.00	Minimal paid-in capital; very limited financial buffer.
Employees	Nil	No workforce; possibly limited operational activity.

Interpretation of Vital Signs:

• The negative net current assets indicate the company’s inability to meet short-term obligations with available current assets, a classic sign of liquidity stress.
• The negative shareholders’ funds reflect accumulated losses eroding equity, signaling ongoing financial weakness or startup phase losses without recovery.
• The minimal share capital suggests limited initial funding or investment cushioning the business.
• The no employees status may mean operations are minimal or outsourced, which can limit cost but also growth potential.

---

3. Diagnosis

The financial "symptoms" of Revolutionary Technologies Group Limited resemble a patient with chronic liquidity issues and a fragile capital structure. The company has consistently reported negative working capital and equity positions over the last four years. This persistent state suggests it is either in an early development phase, investing heavily without revenue generation, or struggling operationally.

The absence of employees and modest liabilities indicate limited scale, but the ongoing negative net assets point to a lack of profitability or insufficient capital injections. The company’s financial "vital signs" reveal a fragile balance sheet that could face difficulties in funding operations or attracting investment without intervention.

The director, who is also the sole significant controller, may be providing informal support or absorbing losses personally. However, without stronger financial health, the company risks creditor pressure or insolvency if the negative trends continue.

---

4. Recommendations

To improve financial wellness and stabilize the company’s monetary "pulse," the following actions are advised:

• Capital Infusion: Consider injecting additional equity or securing shareholder loans to strengthen equity and reduce negative net assets, improving creditor confidence.
• Liquidity Management: Develop a clear cash flow plan to address short-term liabilities. Explore renegotiating payment terms with suppliers or creditors to improve working capital.
• Revenue Generation Strategy: If not already in place, prioritize strategies to increase revenues or monetize intellectual property to reverse losses and build positive reserves.
• Cost Control: Maintain low fixed costs given the absence of employees but monitor any operational expenses closely.
• Financial Monitoring: Implement monthly financial reviews focusing on cash flow metrics and early warning signs of distress.
• Professional Advice: Engage financial advisors or turnaround specialists to assess operational viability and options such as restructuring or phased growth plans.

---

Medical Analogy Summary

Revolutionary Technologies Group Limited currently exhibits symptoms akin to "chronic financial anemia"—a persistent deficit in working capital and equity that weakens its financial "immune system." Without intervention, this condition may worsen, risking insolvency. However, with proper "treatment" via capital support and operational remedies, recovery and a return to "healthy cash flow" are achievable.

---